Shares of Qiagen (NYSE:QGEN - Get Free Report) saw an uptick in trading volume on Monday . 1,375,287 shares changed hands during trading, an increase of 12% from the previous session's volume of 1,230,574 shares.The stock last traded at $43.07 and had previously closed at $42.98.
Analyst Upgrades and Downgrades
Several research firms have recently commented on QGEN. Morgan Stanley raised shares of Qiagen from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $49.48 to $51.00 in a research report on Friday, February 16th. JPMorgan Chase & Co. lifted their target price on shares of Qiagen from $50.00 to $52.00 and gave the stock an "overweight" rating in a research report on Thursday, February 8th. Stifel Nicolaus reduced their target price on Qiagen from $55.00 to $45.00 and set a "hold" rating for the company in a report on Wednesday, May 1st. Finally, Citigroup dropped their price target on Qiagen from $61.86 to $60.00 and set a "buy" rating on the stock in a report on Thursday, February 8th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $50.95.
Check Out Our Latest Analysis on QGEN
Qiagen Price Performance
The business's 50-day moving average price is $42.51 and its 200 day moving average price is $42.80. The company has a quick ratio of 1.45, a current ratio of 1.84 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $9.72 billion, a P/E ratio of 28.55, a price-to-earnings-growth ratio of 3.64 and a beta of 0.42.
Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Monday, April 29th. The company reported $0.46 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.02. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. The company had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. During the same period last year, the business earned $0.53 earnings per share. Qiagen's revenue was down 5.4% compared to the same quarter last year. Analysts anticipate that Qiagen will post 2.09 EPS for the current fiscal year.
Hedge Funds Weigh In On Qiagen
A number of large investors have recently modified their holdings of QGEN. Xponance Inc. raised its stake in Qiagen by 9.1% in the third quarter. Xponance Inc. now owns 9,356 shares of the company's stock valued at $379,000 after purchasing an additional 780 shares in the last quarter. Strs Ohio raised its stake in Qiagen by 14.6% in the third quarter. Strs Ohio now owns 45,441 shares of the company's stock valued at $1,840,000 after purchasing an additional 5,774 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Qiagen by 16.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 255,837 shares of the company's stock valued at $10,361,000 after purchasing an additional 35,297 shares in the last quarter. ING Groep NV raised its stake in Qiagen by 28.4% in the third quarter. ING Groep NV now owns 257,392 shares of the company's stock valued at $10,424,000 after purchasing an additional 56,901 shares in the last quarter. Finally, First Trust Direct Indexing L.P. purchased a new stake in Qiagen in the third quarter valued at approximately $253,000. 70.00% of the stock is currently owned by institutional investors.
About Qiagen
(
Get Free Report)
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Read More
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
